WILMINGTON, Mass., Nov. 3 DUSA Pharmaceuticals, Inc. (Nasdaq: DUSA) announces that its corporate highlights and third quarter financial results press release will be issued on Friday, November 6 at 6:30 a.m. to be followed by a conference call at 8:30 a.m.
Advertisement
The call will be accessible on our web site approximately six hours following the call at www.dusapharma.com.
About DUSA Pharmaceuticals
Advertisement
DUSA Pharmaceuticals, Inc.(® )is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan(®) Photodynamic Therapy technology platform, and complementary dermatology products. Levulan( )PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses of the face and scalp. DUSA also markets other dermatology products, including ClindaReach(®). DUSA is researching Levulan PDT for the treatment of AKs and the prevention of new non-melanoma skin cancer in chronically immunosuppressed solid organ transplant recipients. DUSA is based in Wilmington, Mass. Please visit our web site at www.dusapharma.com.
Friday, November 6 - 8:30 a.m. E.T. If calling from the US or Canada use the following toll-free number: 800.647.4314 Password - DUSA For International callers use 502.498.8422 A recorded replay of the call will be available approximately 15 minutes following the call North American callers 877.863.0350 International callers 858.244.1268
SOURCE DUSA Pharmaceuticals, Inc.
